Axitinib

Licensed by Pfizer Catalog No.S1005 Synonyms: AG 013736

Axitinib Chemical Structure

Molecular Weight(MW): 386.47

Axitinib is a multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ and c-Kit with IC50 of 0.1 nM, 0.2 nM, 0.1-0.3 nM, 1.6 nM and 1.7 nM in Porcine aorta endothelial cells, respectively.

Size Price Stock Quantity  
In DMSO USD 64 In stock
USD 70 In stock
USD 120 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

5 Customer Reviews

  • Representative confocal image (10 x objective) of individual spheroids fixed, sectioned, and then stained for vimentin (green) and DNA (DAPI, blue). Vimentin protein expression from sections quantitated from multiple replicate spheroid treatments with U0126 and axitinib using ImageJ software.

    J Biomol Screen, 2011,16: 141-154. Axitinib purchased from Selleck.

    VimPro-Fluc activity in spheroids after 72-h treatment with control modulators of epithelial-mesenchymal transition (EMT) normalized to spheroid viability and compared to vimentin protein expression using Western blot analysis.

    J Biomol Screen, 2011,16: 141-154. Axitinib purchased from Selleck.

  • Western blot analysis of ERK phosphorylation in HUVECs stimulated for 10 min with AGR2 coupled with or without FGF/VEGF. The concentration of AGR2 is 500 ng/ml. The concentration of VEGF is 5 ng/ml. PD173074: FGFR inhibitor; Axitinib: VEGFR inhibitor (2 nm); BEV: VEGF antibody bevacizumab (5 μg/ml). Quantification of ERK activity was performed by normalizing phosphorylated ERK to β-actin, untreated control (lane 1) was set to 1. All data represent four independent biological replicates and shown as means±s.d. Asterisks indicate significant differences (*, Pless than or equal to0.05; **, Pless than or equal to0.01).

    Oncogene, 2017, 36(36):5098-5109. Axitinib purchased from Selleck.

    Secondary assay development. The invasive potential of MDA-MB-231 spheroids was measured using modified Boyden chambers coated with Matrigel™. Invading cells were fixed, stained with DAPI, and quantified by fluorescence microscopy using 5 random fields per filter insert in triplicate. U0126, PF2341066, axitinib, and PKC412 inhibited the invasive potential of MDA-MB-231 spheroids by ~90% as compared to untreated spheroids (UT). ***p ≤ 0.001. IGF1R and dasatinib displayed no statistical difference as compared to UT MDA-MB-231 spheroids.

    J Biomol Screen 2011 16, 141-154. Axitinib purchased from Selleck.

  • Axitinib treatment blocks VEGFR2 phosphorylation.

    HUVECs were starved O/N in EBM-2 basal medium with 1% FBS and antibiotic. Cells were pre-treated with Axitinib at 0.1, 1 and 10 nM concentrations. VEGF stimulation was 50 ng/ml for 10 minutes before cells were collected and protein isolated for immunoprecipitation with VEGFR2 followed by immunoblotting with VEGFR-2 and phospho-VEGFR-2.

     

     

    Dr. Cheri Pasch of UW Madison. Axitinib purchased from Selleck.

Purity & Quality Control

Choose Selective VEGFR Inhibitors

Biological Activity

Description Axitinib is a multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ and c-Kit with IC50 of 0.1 nM, 0.2 nM, 0.1-0.3 nM, 1.6 nM and 1.7 nM in Porcine aorta endothelial cells, respectively.
Features Superior as second-line therapy relative to sorafenib (current standard-of-care).
Targets
VEGFR1/FLT1 [1]
(Porcine aorta endothelial cells)
VEGFR2/Flk1 [1]
(Porcine aorta endothelial cells)
VEGFR2/KDR [1]
(Porcine aorta endothelial cells)
VEGFR3 [1]
(Porcine aorta endothelial cells)
PDGFRβ [1]
(Porcine aorta endothelial cells)
0.1 nM 0.18 nM 0.2 nM 0.1 nM-0.3 nM 1.6 nM
In vitro

Axitinib could block the cellular autophosphorylation of VEGFR and VEGF-mediated endothelial cell viability, tube formation, and downstream signaling. Axitinib inhibits the proliferation of variable cell lines with IC50 of >10,000 nM (IGR-N91), 849 nM (IGR-NB8), 274 nM (SH-SY5Y) and 573 nM (non-VEGF stimulated HUVEC). [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
EoL-1-cell NVHGXnBET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjEZ|VsUUN3ME2wMlAxODB3MUOg{txO MVfTRW5ITVJ?
NCI-H1703 NFjBU2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonXTWM2OD1yLkCwNFkxOiEQvF2= NGjsUmVUSU6JRWK=
KASUMI-1 Ml:yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTBwMEC2PFIh|ryP MmXwV2FPT0WU
CGTH-W-1 MmDrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULMNJZ1UUN3ME2wMlAxPzJ{IN88US=> MX;TRW5ITVJ?
A204 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\BR2dKSzVyPUCuNFA6QTJizszN NYXRUFBEW0GQR1XS
HOP-62 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPvd2dKSzVyPUCuNVA5OzZizszN MV7TRW5ITVJ?
H-EMC-SS MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIO2OFRKSzVyPUCuNVExODVizszN MVHTRW5ITVJ?
KU812 Mn3qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zidWlEPTB;MD6xOlU4PyEQvF2= MnHEV2FPT0WU
EM-2 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjydmRKSzVyPUCuNVY5OTZizszN MVvTRW5ITVJ?
LAMA-84 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rOXGlEPTB;MD6xO|Y3PSEQvF2= Ml:0V2FPT0WU
JAR M4PveWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmj6TWM2OD1yLkKzPVg6KM7:TR?= NFfMV3lUSU6JRWK=
G-361 NUCwNpNpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTBwM{KzNlUh|ryP M2PyO3NCVkeHUh?=
KG-1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHHfms5UUN3ME2wMlM4PjR{IN88US=> Mn\rV2FPT0WU
BV-173 NUDwWpJnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\0TWM2OD1yLkO5N|Ih|ryP NUPMUpF5W0GQR1XS
K5 NUCzW5BjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHkVWxKSzVyPUCuOFIyOjdizszN MXnTRW5ITVJ?
MEG-01 NFrhSmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXsTWM2OD1yLkSyN|YyKM7:TR?= MlX6V2FPT0WU
MFM-223 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTBwNES3O|Yh|ryP NFL3dldUSU6JRWK=
BE-13 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jNTmlEPTB;MD61NVAxQCEQvF2= M{fyOnNCVkeHUh?=
NEC8 NVO5PIpnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDVWZlKSzVyPUCuO|IyOTNizszN NUjGRWt2W0GQR1XS
SW756 MknyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13SOmlEPTB;MD65PVg1PiEQvF2= M1PiVHNCVkeHUh?=
A2780 MmX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTBR2c5UUN3ME2xMlAyOTR4IN88US=> MVnTRW5ITVJ?
NB14 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfNTWZKSzVyPUGuNFE5ODFizszN MorhV2FPT0WU
H4 NXHWfmFuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HJNmlEPTB;MT6wOlQzOiEQvF2= M3nEbnNCVkeHUh?=
SK-OV-3 M{mwUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnibXNkUUN3ME2xMlA3PjN|IN88US=> MXHTRW5ITVJ?
AN3-CA NGS0bmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInMNFBKSzVyPUGuNFg{QDlizszN MkDsV2FPT0WU
A427 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3y1TmlEPTB;MT6xNFM5OSEQvF2= NIfQVoZUSU6JRWK=
ES7 M3jMOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXETWM2OD1zLkGxN|M1KM7:TR?= NXvVUXJGW0GQR1XS
AGS MmGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTFwMUGzPVUh|ryP MXzTRW5ITVJ?
G-402 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTFwMUS2PVQh|ryP MmrIV2FPT0WU
ES5 NU\KW5FkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHz5OIFKSzVyPUGuNVczPDhizszN MU\TRW5ITVJ?
DEL NF;vU4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTFwMkW0OVch|ryP NEXCZ5NUSU6JRWK=
NB10 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTFwM{K1OVch|ryP M3HyNnNCVkeHUh?=
NCI-H1581 Ml:0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnxNGs5UUN3ME2xMlM6ODR{IN88US=> MVnTRW5ITVJ?
D-566MG NYfW[2pzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonUTWM2OD1zLkSwOlg{KM7:TR?= MWfTRW5ITVJ?
LXF-289 NYL3TGljT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTFwNEO5PVYh|ryP NFezWHJUSU6JRWK=
BT-549 NWjaeplFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTFwNU[5NFkh|ryP MXXTRW5ITVJ?
NKM-1 MnS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zCdWlEPTB;MT62NFU2PiEQvF2= M4KzTHNCVkeHUh?=
SW780 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HpOWlEPTB;MT62OVE2QCEQvF2= NGjjPHlUSU6JRWK=
NCI-H292 NWHiO4d1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn76TWM2OD1zLk[2N|g{KM7:TR?= MY\TRW5ITVJ?
HMV-II NVfU[WxQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTFwN{C0PFgh|ryP M1nvUnNCVkeHUh?=
ALL-PO MmfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTFwOECwNVUh|ryP NWCwR4NQW0GQR1XS
UACC-257 NF;QOWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fhXmlEPTB;MT64NlE3OyEQvF2= NVK0UZNOW0GQR1XS
PA-1 MlzGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXTTWM2OD1zLkiyO|I2KM7:TR?= NHnQcIFUSU6JRWK=
HD-MY-Z MknzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlX4TWM2OD1zLki2NlgyKM7:TR?= NIXIT4VUSU6JRWK=
HSC-4 MofmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fyfmlEPTB;MT65N|g{QSEQvF2= NH7VN5FUSU6JRWK=
GCT NYXHNmJyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDxZm0{UUN3ME2yMlAxQTF4IN88US=> MnPOV2FPT0WU
RT-112 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fMcmlEPTB;Mj6xN|QzPCEQvF2= M4fJ[3NCVkeHUh?=
A172 M13iOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfKephKSzVyPUKuNVM3ODZizszN M4OxfHNCVkeHUh?=
HCE-T Ml\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PGbWlEPTB;Mj6yNFU6QCEQvF2= M3WzSXNCVkeHUh?=
YH-13 M{\tdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXWTWM2OD1{LkKxOlcyKM7:TR?= NGT0RW5USU6JRWK=
DK-MG NYq2W3Q3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjydZF2UUN3ME2yMlI{QDN2IN88US=> NWXuOJB5W0GQR1XS
ACN NXnIWlB6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrzT4c1UUN3ME2yMlI{QDd3IN88US=> Mny3V2FPT0WU
VA-ES-BJ MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLLO5dKSzVyPUKuNlQ6PTdizszN MY\TRW5ITVJ?
L-363 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVe0eoNmUUN3ME2yMlI5ODZzIN88US=> MXzTRW5ITVJ?
HuH-7 MkXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPHTWM2OD1{LkSyNVY2KM7:TR?= NUfBeXd6W0GQR1XS
A4-Fuk NVroZlQ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HN[GlEPTB;Mj60O|E3QCEQvF2= NV\sZoR6W0GQR1XS
T-24 M3PpVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGn2SnNKSzVyPUKuOFgxOzdizszN NHjBS4ZUSU6JRWK=
GOTO M2nJfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLreZJKSzVyPUKuOVMxOTNizszN M1nFRnNCVkeHUh?=
MV-4-11 NHzKdFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonoTWM2OD1{LkW5NVY6KM7:TR?= NXrYSHY{W0GQR1XS
DMS-114 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjMTWM2OD1{Lk[2N|Q2KM7:TR?= NFv0cItUSU6JRWK=
MHH-NB-11 M2P4RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnL0TWM2OD1{LkewNlk6KM7:TR?= NYL6Z41LW0GQR1XS
CHP-212 MoHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTJwOEKwPVEh|ryP MmriV2FPT0WU
DMS-273 NIfMdWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXl[VFRUUN3ME2yMlkxOjB5IN88US=> NX23WJFuW0GQR1XS
SF295 M135[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTNwMEK1PVch|ryP M1X5VnNCVkeHUh?=
NCI-H1563 NVv5O2o4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFH4ZnZKSzVyPUOuNVUxODVizszN NYTUbZpQW0GQR1XS
NCI-H446 NEPoN|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4i0WWlEPTB;Mz6yNlgxPSEQvF2= M{L1bnNCVkeHUh?=
HCC1806 M4PWWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{ToemlEPTB;Mz6yO|Y2PyEQvF2= M17uOHNCVkeHUh?=
SF126 MnjGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTNwM{CwNVch|ryP M3PrdHNCVkeHUh?=
SW982 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7OOmZKSzVyPUOuN|M5PzVizszN Ml;1V2FPT0WU
ES8 NWrkTWpDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFH4RYtKSzVyPUOuN|Q6QTlizszN NE\iS2pUSU6JRWK=
SCC-4 M2S1OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HGVGlEPTB;Mz61NFM6PiEQvF2= MnjzV2FPT0WU
RPMI-8226 NEjOR5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGX1bG1KSzVyPUOuOlI3OTZizszN MV\TRW5ITVJ?
EW-11 Ml;YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LDOWlEPTB;Mz62N|AzOiEQvF2= M4rHUnNCVkeHUh?=
COR-L105 MnXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTNwNkOzN|Qh|ryP NUXsdZJqW0GQR1XS
ES1 NU[1dXJPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljmTWM2OD1|LkizNFk1KM7:TR?= NFHMNYVUSU6JRWK=
KMOE-2 NEDJNpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XjdmlEPTB;Mz65NVgxQCEQvF2= NFf3TVRUSU6JRWK=
ABC-1 M{n0fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlf6TWM2OD1|LkmzPVEyKM7:TR?= MWXTRW5ITVJ?
NCI-H526 NIPsNFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;ETWM2OD1|Lkm5NVI3KM7:TR?= NXjPV3g4W0GQR1XS
HCC1395 NYfhSVlrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVize3V6UUN3ME2zMlk6PDh2IN88US=> M3i1bXNCVkeHUh?=
DU-145 NYX2Nmg6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLIXY5lUUN3ME20MlEzQDJ3IN88US=> NFj4PYpUSU6JRWK=
JEG-3 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTRwMUW5NVYh|ryP MV3TRW5ITVJ?
HCC1187 M{nUb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17CNGlEPTB;ND6yNVU6PyEQvF2= MXPTRW5ITVJ?
LC-2-ad MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3TW3c2UUN3ME20MlIzOTd5IN88US=> NYf2eFRHW0GQR1XS
ONS-76 NILOUYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHpTWM2OD12LkK0NVkzKM7:TR?= NYq0d|RkW0GQR1XS
CAL-27 MnrLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfuTWM2OD12LkK0N|Q1KM7:TR?= MoXwV2FPT0WU
8-MG-BA MlPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLndJhKSzVyPUSuNlY3PThizszN M1nQfHNCVkeHUh?=
HGC-27 M4HvNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjLTWM2OD12LkK5OlYh|ryP NH3seGVUSU6JRWK=
Hs-578-T M{PwXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrXO4lKSzVyPUSuN|E1PjhizszN Mm\VV2FPT0WU
EW-1 NEnvXYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;BUFZKSzVyPUSuOVMxOTRizszN M4\FXXNCVkeHUh?=
SW1573 NWTOZlhxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TwfWlEPTB;ND61OVE3OyEQvF2= NVnLfGJ2W0GQR1XS
SNU-423 MnrDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\5OXloUUN3ME20MlYxPzlizszN M{nRTnNCVkeHUh?=
HOS NXyycZdHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mom3TWM2OD12Lk[5O|ch|ryP NFTlNWJUSU6JRWK=
LB1047-RCC M{POPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTRwOEG0NVgh|ryP NHLhd2lUSU6JRWK=
ChaGo-K-1 NV3rUJFiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULWfZZqUUN3ME20Mlg6ODR6IN88US=> M4fYfXNCVkeHUh?=
A3-KAW NH3kOotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTSTWM2OD12Lkm3N|UzKM7:TR?= NHTJbldUSU6JRWK=
CAS-1 M2nMT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DsdWlEPTB;ND65PVkxQCEQvF2= NH3tNFlUSU6JRWK=
NBsusSR NVXRfGRpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4ryVGlEPTB;NT6wN|UyPCEQvF2= NVHpSGI2W0GQR1XS
KM12 NFjOUYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3zNWNpUUN3ME21MlI6QDJ5IN88US=> M1fRR3NCVkeHUh?=
NCI-H1155 MkS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MluyTWM2OD13LkO4NVg2KM7:TR?= NV3aSZBqW0GQR1XS
EFM-19 NUfZNHE2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTreIp{UUN3ME21MlQyPzN5IN88US=> MkLBV2FPT0WU
D-392MG MlzlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvaU41kUUN3ME21MlU4QDR7IN88US=> M1XNfXNCVkeHUh?=
JVM-3 NEPjSJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUf5Z|h1UUN3ME21MlczOzJ3IN88US=> MlP3V2FPT0WU
EW-16 NULn[4g6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPzO29KSzVyPUWuO|U2QDNizszN M17zNXNCVkeHUh?=
KARPAS-45 NIfLW5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoX0TWM2OD13Lki0N|I2KM7:TR?= MX;TRW5ITVJ?
NCI-H28 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTkS4lWUUN3ME21Mlg4QTF6IN88US=> NEPHR2JUSU6JRWK=
COLO-829 MmDGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmr2TWM2OD13LkmxOVA1KM7:TR?= MnrRV2FPT0WU
KM-H2 NVGyW5dDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTVwOUKzPVUh|ryP MnPOV2FPT0WU
NCI-H82 NVSxO4c3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17jN2lEPTB;NT65Nlc4OSEQvF2= NWWwOWxkW0GQR1XS
OAW-42 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{D2ZWlEPTB;NT65PFgzOSEQvF2= MmXqV2FPT0WU
A704 M{fwXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnmyTWM2OD14LkGwOVc1KM7:TR?= MVrTRW5ITVJ?
NCI-H1048 NEn5bI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTZwMUC1PVkh|ryP MXPTRW5ITVJ?
LOXIMVI M4n2cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPCT2p{UUN3ME22MlEyOjR6IN88US=> NV7tc|dLW0GQR1XS
MKN45 NYj4cmV3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXNSnpKSzVyPU[uNlYxOTZizszN NFzYO4lUSU6JRWK=
D-502MG NXmxcJZFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXZRplJUUN3ME22MlI5QDV5IN88US=> NY\ufHJ3W0GQR1XS
HUTU-80 NUfkOJFiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTZwNEG2PFgh|ryP MV\TRW5ITVJ?
S-117 Mn\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4f6PWlEPTB;Nj61NFI3PyEQvF2= MVjTRW5ITVJ?
HCC1569 NFrqe2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTZwNUO3N|ch|ryP MVLTRW5ITVJ?
J-RT3-T3-5 M3HXbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGP6fYNKSzVyPU[uOVQ2PzJizszN NF\PPXlUSU6JRWK=
OC-314 NFj3NopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLCdmFKSzVyPU[uPVEyPTlizszN MlvwV2FPT0WU
SNU-449 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\KTWM2OD15LkCxNFczKM7:TR?= Ml7vV2FPT0WU
NCI-H720 MlHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1e2OmlEPTB;Nz6xPVM1PSEQvF2= MYfTRW5ITVJ?
KP-N-YS NYi1XZlRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1yzXWlEPTB;Nz6yNFczKM7:TR?= NHLMNZRUSU6JRWK=
IGROV-1 M4P0U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrTfJJKSzVyPUeuN|I{QDZizszN M4rkRXNCVkeHUh?=
SK-PN-DW NHezWXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mme0TWM2OD15LkS4NVUh|ryP M{XHPHNCVkeHUh?=
HCC1419 M3ziZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTdwNUOg{txO M2XRbHNCVkeHUh?=
HAL-01 NHG0[oJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPYSXlKSzVyPUeuOlA3PDRizszN MnnhV2FPT0WU
HCC2998 M13ufGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTdwNkC3OFMh|ryP NIHaTlNUSU6JRWK=
SK-N-FI NF3v[XBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvJbGpxUUN3ME23MlY{ODN|IN88US=> NFHuNYZUSU6JRWK=
GI-ME-N M1PDXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLzTWM2OD15Lk[0PVM1KM7:TR?= NX;5fnV7W0GQR1XS
SW1088 NE[0bmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3uyOWlEPTB;Nz62OVgzPiEQvF2= Mor6V2FPT0WU
IA-LM M4PwSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\zPIRKSzVyPUeuOlg3OTNizszN MmO5V2FPT0WU
SK-NEP-1 NFrJdIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NESwTGlKSzVyPUeuOlk3OSEQvF2= NHv0d4lUSU6JRWK=
MDA-MB-415 M1vlc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTdwOEmxPFYh|ryP NVu0RowzW0GQR1XS
COLO-800 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\WfYY1UUN3ME23Mlk1PDl{IN88US=> MV3TRW5ITVJ?
NCI-H2228 NUj5VJVTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmD6TWM2OD16LkG1O|g{KM7:TR?= MUTTRW5ITVJ?
D-423MG M2OwZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvJeIFoUUN3ME24MlIyPzJizszN NXHIT2tJW0GQR1XS
TE-1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoX4TWM2OD16LkS0N|E3KM7:TR?= Mm\sV2FPT0WU
NOS-1 NUPaeFhIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDpZ2lkUUN3ME24MlUyPTN2IN88US=> NXnHPXk1W0GQR1XS
8505C NY\rW|dVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRThwNkS4NlQh|ryP MnzVV2FPT0WU
HEC-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnRUnZmUUN3ME24Mlc5PDN7IN88US=> NUS1TYJVW0GQR1XS
TE-11 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;sTWM2OD16Lkm5OVUyKM7:TR?= MXvTRW5ITVJ?
CTB-1 MnLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGCzPZVKSzVyPUmuNFE1OzNizszN M3ztcXNCVkeHUh?=
TGBC11TKB MnfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTlwMEKyOFEh|ryP NGDXXWdUSU6JRWK=
NB17 NWW0[XRWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;iemlEPTB;OT6xPFg4KM7:TR?= MVLTRW5ITVJ?
Becker NHXYOpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULZW|g1UUN3ME25MlQyQTR2IN88US=> MmCxV2FPT0WU
SN12C MmTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4Dob2lEPTB;OT60OVI{PCEQvF2= M3vReHNCVkeHUh?=
COLO-320-HSR NWHoUIJ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTlwNkCyN|ch|ryP M4W3bXNCVkeHUh?=
D-283MED MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTuOVVKSzVyPUmuOlMxPzJizszN NXW1UW5UW0GQR1XS
D-263MG M1vL[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIC1b4xKSzVyPUmuPFM{QDRizszN MXHTRW5ITVJ?
MEL-JUSO NHPNbJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTlwOUCxNlch|ryP NWLvZ4VGW0GQR1XS
T98G M4TEXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTlwOUCyNFMh|ryP NULwS5FQW0GQR1XS
HLE NHLYdGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nscGlEPTB;OT65NFkxQSEQvF2= NHf5O|BUSU6JRWK=
Ca9-22 Ml\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHxTWM2OD1zMD6wOlY2KM7:TR?= NIjvTm5USU6JRWK=
OS-RC-2 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYn0OXBPUUN3ME2xNE4yODR3IN88US=> MU\TRW5ITVJ?
T47D MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTFyLkG1OUDPxE1? M4PPXnNCVkeHUh?=
GI-1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPqTWM2OD1zMD6zOVM{KM7:TR?= NF30ZotUSU6JRWK=
NUGC-3 NYDFc3A2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TWVmlEPTB;MUCuOFQxOiEQvF2= NF72UZVUSU6JRWK=
MDA-MB-361 NY\uOFNDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHGycYpKSzVyPUGwMlQ1OzJizszN NIfDVGlUSU6JRWK=
SCC-15 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTrTWM2OD1zMD60O|E5KM7:TR?= M4X1e3NCVkeHUh?=
KS-1 Mkm5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTFyLk[zNFEh|ryP NV7L[IlQW0GQR1XS
CAL-12T MkHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4OwVGlEPTB;MUCuOlM3OSEQvF2= MorFV2FPT0WU
OVCAR-4 M2rScmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHe0fYlKSzVyPUGwMlcxPjhizszN MlyzV2FPT0WU
HuP-T4 MkGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTFzLkCzNlgh|ryP MWjTRW5ITVJ?
NCI-H358 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2Gwe2lEPTB;MUGuNlY2PyEQvF2= MoiwV2FPT0WU
HO-1-N-1 NUXPV4ZNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;vXmlEPTB;MUGuN|M6QCEQvF2= NYW0TXJwW0GQR1XS
NH-12 MoezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH6xZpRKSzVyPUGxMlU{PzhizszN NWHwUW5QW0GQR1XS
MOLT-4 NYXRO5RnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLrfGJuUUN3ME2xNU42QTh3IN88US=> MYjTRW5ITVJ?
K-562 M{W3cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2H1emlEPTB;MUGuO|I1QCEQvF2= M4L1UnNCVkeHUh?=
ES6 Mnq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTHTWM2OD1zMT64OVgyKM7:TR?= NGDNVVhUSU6JRWK=
RO82-W-1 M4X3PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTFzLkmwOlQh|ryP M{fIdHNCVkeHUh?=
Ramos-2G6-4C10 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjkTWM2OD1zMT65N|Ih|ryP M4Xi[nNCVkeHUh?=
23132-87 NUHUeFNkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnWzTWM2OD1zMj6wPFIyKM7:TR?= MlP0V2FPT0WU
A549 NV:5bndLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTF{LkOyPFUh|ryP M{CxRnNCVkeHUh?=
NCI-H23 NWLoe4R1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHVT3U6UUN3ME2xNk42ODJ4IN88US=> NF3DSZRUSU6JRWK=
H9 NFToPFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4Hab2lEPTB;MUKuOVU4PyEQvF2= M1TFOHNCVkeHUh?=
LB771-HNC MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTF{Lke2OUDPxE1? NG\ob5lUSU6JRWK=
QIMR-WIL NELud5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTF{LkiyOVgh|ryP NEjueWFUSU6JRWK=
HSC-3 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGGxZXBKSzVyPUGyMlkzPzZizszN M4HDNHNCVkeHUh?=
PFSK-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfqSXM5UUN3ME2xNk46PTB5IN88US=> MWPTRW5ITVJ?
ETK-1 Mn;GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnqXpBKSzVyPUGzMlA4PzlizszN MV3TRW5ITVJ?
SW1710 Ml\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDW[5pKSzVyPUGzMlM3PDFizszN NIDRVmFUSU6JRWK=
COLO-684 NV25eGR4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTF|LkS1OFEh|ryP Ml;wV2FPT0WU
RPMI-7951 M3XrOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTF|LkWxN|Yh|ryP Mo\rV2FPT0WU
A101D MlvqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkW4TWM2OD1zMz61N|Q6KM7:TR?= NH\rZnpUSU6JRWK=
KE-37 M1qzbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rDZ2lEPTB;MUOuOVg5PyEQvF2= Mkn5V2FPT0WU
SiHa MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjQTWM2OD1zMz64N|Q3KM7:TR?= NG\jV3VUSU6JRWK=
NCI-H226 NGryeoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TPfmlEPTB;MUOuPFgxQCEQvF2= Mkm3V2FPT0WU
DB NG\adHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTF|Lkm5Nlgh|ryP MnXhV2FPT0WU
HT-1197 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHKx[3JKSzVyPUG0MlA5ODlizszN NUDuUW11W0GQR1XS
SBC-5 NFnLXlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTF2LkGzOlIh|ryP M3vC[HNCVkeHUh?=
VMRC-RCZ MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTXc5Y1UUN3ME2xOE42Pzd2IN88US=> MoLJV2FPT0WU
697 NWTweWhTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTF2Lk[yO{DPxE1? MnzRV2FPT0WU
OMC-1 NHfV[HVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoeyTWM2OD1zND63PFg5KM7:TR?= MX3TRW5ITVJ?
SKG-IIIa M1qzNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrt[nZKSzVyPUG0MlgxODFizszN M2\oTXNCVkeHUh?=
DOK Mk\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTF2Lkm5N|Mh|ryP M2HUWHNCVkeHUh?=
NCI-H2029 NYLOZZFbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjlTWM2OD1zNT6zOlAzKM7:TR?= NXzzPGpVW0GQR1XS
NCI-H2009 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTF3LkWwPVUh|ryP NXPmdYN{W0GQR1XS
LK-2 MkPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NViwZmJTUUN3ME2xOU43PDR7IN88US=> NUHlcmt2W0GQR1XS
NCI-H661 NYjteXFET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3jjUWlEPTB;MUWuPVA4PSEQvF2= Mlr0V2FPT0WU
GT3TKB M4rnTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTF4LkC2O|Yh|ryP MnfMV2FPT0WU
GP5d NFTENVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HNPWlEPTB;MU[uN|QzKM7:TR?= M2\JPHNCVkeHUh?=
SK-MEL-2 NWj2d2hjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLPRWZYUUN3ME2xOk41PDh3IN88US=> M{jaenNCVkeHUh?=
SK-UT-1 MnroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHnSlVKSzVyPUG2MlU3PSEQvF2= NGjBS2JUSU6JRWK=
NB7 NYrrRWJFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnv5TWM2OD1zNj62PVcyKM7:TR?= NIHZPG5USU6JRWK=
NCI-H460 MmDyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XVe2lEPTB;MU[uO|MzPiEQvF2= M16wfXNCVkeHUh?=
8305C MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XMVmlEPTB;MU[uO|g4PyEQvF2= MV3TRW5ITVJ?
CaR-1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfHTWM2OD1zNj64NVEyKM7:TR?= NGjEZ2tUSU6JRWK=
D-247MG MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHmxdYRKSzVyPUG2Mlg3OjVizszN MmD0V2FPT0WU
LoVo NIXQSY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHab3FKSzVyPUG2Mlk1QDhizszN MYXTRW5ITVJ?
NCI-H2405 NHzzTGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPHWnJKSzVyPUG3MlE6ODhizszN MY\TRW5ITVJ?
AU565 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;5TWM2OD1zNz6yNlUh|ryP M33UdXNCVkeHUh?=
OCI-AML2 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTF5LkWzNVch|ryP NEfrboNUSU6JRWK=
22RV1 MoHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXPfo5jUUN3ME2xO{42QDh2IN88US=> MnrUV2FPT0WU
HT-144 NYPlT5RDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mke5TWM2OD1zNz62OVk5KM7:TR?= M4TEOXNCVkeHUh?=
HuO9 M3uxfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnmb5RKSzVyPUG3MlcxOzFizszN M3nxeXNCVkeHUh?=
Daoy NEXTW21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1P6UWlEPTB;MUeuO|E5PCEQvF2= NYGyVWRzW0GQR1XS
SJRH30 NFPHU45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rEXWlEPTB;MUeuPFQ5QSEQvF2= M13LWHNCVkeHUh?=
CHL-1 NYH5PVZbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXuTodoUUN3ME2xO{46OjR7IN88US=> MYjTRW5ITVJ?
J82 NUSx[HBzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rlWGlEPTB;MUeuPVY{PSEQvF2= NULGbFdMW0GQR1XS
COR-L23 NGjHZZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\nelQyUUN3ME2xPE4xODFzIN88US=> MkLsV2FPT0WU
SNU-C2B MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTF6LkKyO|Yh|ryP MVzTRW5ITVJ?
NCI-H1770 NUXTcGtPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnPdYZ4UUN3ME2xPE41PjF3IN88US=> NGK2eZBUSU6JRWK=
MHH-PREB-1 M4rIUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjDTWM2OD1zOD61Olk4KM7:TR?= NVvncowxW0GQR1XS
ES3 NY\JU3JsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTF6LkW4PFMh|ryP MWrTRW5ITVJ?
MDA-MB-231 NXvZc29QT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzGe3d2UUN3ME2xPE43PTB{IN88US=> NWDW[|k{W0GQR1XS
MN-60 M3X1Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV6xV213UUN3ME2xPU4xPTl{IN88US=> NFK3PHlUSU6JRWK=
EPLC-272H NVnDTmF1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnscZZKSzVyPUG5MlM4ODhizszN MWLTRW5ITVJ?
SW948 MlvuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDVRmY6UUN3ME2xPU4{QTN2IN88US=> MnGzV2FPT0WU
MOLT-13 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rRdGlEPTB;MUmuOFU1PiEQvF2= MlzUV2FPT0WU
HL-60 NX7yNpJGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnmTWM2OD1{MD6yNVQyKM7:TR?= Mn;RV2FPT0WU
CP50-MEL-B MkLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfiSlVVUUN3ME2yNE41PzR6IN88US=> MWrTRW5ITVJ?
NTERA-S-cl-D1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGm2SGVKSzVyPUKwMlQ6PzhizszN NFjqWnBUSU6JRWK=
KINGS-1 NH\GUFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXhdHNKSzVyPUKwMlc6PjdizszN MlzvV2FPT0WU
DOHH-2 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrsRVFKSzVyPUKwMlkxPiEQvF2= NY\xUFd1W0GQR1XS
BB65-RCC NYP6VWR1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnzUXplUUN3ME2yNE46Ojh3IN88US=> MWLTRW5ITVJ?
NB12 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLjV3VKSzVyPUKxMlA{QTRizszN M3fwOXNCVkeHUh?=
KY821 NV7VT|Z3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPKTWM2OD1{MT61PFIh|ryP NWSyenh[W0GQR1XS
PSN1 MoTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPKN|NKSzVyPUKxMlY1PTNizszN NYnUeo1[W0GQR1XS
EGI-1 M2C4WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo[0TWM2OD1{MT63OFU1KM7:TR?= M33GeHNCVkeHUh?=
CTV-1 NX33d2JJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\M[2lLUUN3ME2yNk4{ODNzIN88US=> NESwSGZUSU6JRWK=
TI-73 NGTxZppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PpR2lEPTB;MkKuN|Q6QCEQvF2= NXv3WVhyW0GQR1XS
LCLC-103H M{DTZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3nTWM2OD1{Mj60O|UzKM7:TR?= MULTRW5ITVJ?
D-542MG NED1V21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVe3WnBqUUN3ME2yNk42PTV6IN88US=> NHXydXJUSU6JRWK=
ATN-1 Mkn6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jIfWlEPTB;MkKuOlQ{QSEQvF2= M3:wOXNCVkeHUh?=
SK-MEL-1 Mn7pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTJ{LkizOlgh|ryP MX7TRW5ITVJ?
HDLM-2 NVjpXW9rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7YVmxKSzVyPUKzMlE1PzhizszN MX\TRW5ITVJ?
UM-UC-3 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{D6bWlEPTB;MkOuNVk1PCEQvF2= NV7ue41CW0GQR1XS
NCI-H1573 NH3RO4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTJ|LkS2PFEh|ryP NW\3VnBbW0GQR1XS
NCI-H520 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTJ|LkS5OFgh|ryP NFniT5RUSU6JRWK=
ESS-1 M2W5UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LkSWlEPTB;MkOuPFA2QSEQvF2= MnLQV2FPT0WU
COR-L88 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTJ|Lkm0O|Uh|ryP NHfWdFFUSU6JRWK=
TGBC24TKB NV3lSoFJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TDd2lEPTB;MkSuNFMyOiEQvF2= NIHwXXdUSU6JRWK=
HCC1937 NHHIXIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTHTWM2OD1{ND6xJO69VQ>? MnXQV2FPT0WU
RS4-11 Mln4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTVbW9KSzVyPUK0MlE1OiEQvF2= NVjUfmZmW0GQR1XS
HCC38 NVL5b49YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4noTmlEPTB;MkSuNlM6PCEQvF2= NHHBcVBUSU6JRWK=
RPMI-2650 NWfp[XpmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUK4e5F6UUN3ME2yOE43OTZ{IN88US=> MoXnV2FPT0WU
P12-ICHIKAWA NV\meXNLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPhb2ZKSzVyPUK0MlYzPThizszN M1rON3NCVkeHUh?=
YAPC NFvCSWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4K3VmlEPTB;MkSuPFIyPCEQvF2= MmrmV2FPT0WU
NB13 Mm\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmCzTWM2OD1{NT6yOlEyKM7:TR?= Ml;1V2FPT0WU
SK-N-AS M2WwWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELlemVKSzVyPUK1Mlg2QDRizszN NYTyRodsW0GQR1XS
SK-N-DZ NWTqZ2JyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTJ4LkC0PUDPxE1? NWK2Z3pSW0GQR1XS
LS-411N MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofmTWM2OD1{Nj6yNFM5KM7:TR?= NXy3Z41ZW0GQR1XS
NCI-H810 NEjoW3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DMbGlEPTB;Mk[uN|EyOiEQvF2= MlTSV2FPT0WU
NCI-SNU-1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnG2TWM2OD1{Nj61OFU1KM7:TR?= MUDTRW5ITVJ?
HH NEOwPZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmm1TWM2OD1{Nj61OVI6KM7:TR?= Mlq4V2FPT0WU
U-2-OS NUS1OG5sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPUTWM2OD1{Nj63N|gzKM7:TR?= MmD6V2FPT0WU
SF539 NETsNZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{ixWWlEPTB;Mk[uPFAyQCEQvF2= MX7TRW5ITVJ?
NCI-H2052 NHnpTohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlviTWM2OD1{Nz6wPFYh|ryP NF7UOo1USU6JRWK=
A673 NG[2XVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\ZWGlEPTB;MkeuNlExOiEQvF2= MVrTRW5ITVJ?
WM-115 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTJ5Lke3Olch|ryP NUXkPYVmW0GQR1XS
SW48 NUjQWlRuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTJ5LkiwNFUh|ryP M{K2UXNCVkeHUh?=
NOMO-1 M{L5PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXZW2VKSzVyPUK3Mlg2OzJizszN NILuUFBUSU6JRWK=
PC-3 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjLZXQ3UUN3ME2yO{45QTRzIN88US=> NUnxNZZpW0GQR1XS
UMC-11 NVflPY9rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH23dmpKSzVyPUK3Mlk{PDNizszN MknvV2FPT0WU
U-118-MG M13xOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTJ6LkCxNlMh|ryP MonJV2FPT0WU
NCI-H2452 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\GeGlEPTB;MkiuNFgzOiEQvF2= NYTkWI9ZW0GQR1XS
CAMA-1 NHPKV4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTJ6Lki1OlQh|ryP NXvOTlJxW0GQR1XS
MC-IXC MmfYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTJ7LkKzOlYh|ryP NWfEfmlUW0GQR1XS
ES4 NHXSO2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfnTWM2OD1{OT6zNVczKM7:TR?= M4TsR3NCVkeHUh?=
BHT-101 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnmXlNYUUN3ME2yPU4{OjFizszN Mn;HV2FPT0WU
KP-4 M3Hpcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPJTWM2OD1{OT61NVYh|ryP NFT3R2pUSU6JRWK=
CAL-54 MmfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLxbZl1UUN3ME2yPU42PDR3IN88US=> NF\3ZWJUSU6JRWK=
5637 MmXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jEZ2lEPTB;MkmuOlQzOSEQvF2= MWPTRW5ITVJ?
MOLT-16 M1;GcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnQ[|ZzUUN3ME2yPU44OjZ7IN88US=> NYrqfYc{W0GQR1XS
Ca-Ski M4TZeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjWblJKSzVyPUK5Mlk1PiEQvF2= MVfTRW5ITVJ?
AsPC-1 NV6zcGhJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2K5O2lEPTB;M{CuNFIyOiEQvF2= M3PBdHNCVkeHUh?=
MSTO-211H MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2Tu[mlEPTB;M{CuNVUh|ryP NVjze2l7W0GQR1XS
L-428 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXUTWM2OD1|MD60NFUh|ryP NYWybG0xW0GQR1XS
SW1463 MnmzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTNyLkWzPFMh|ryP NYfxZ5c6W0GQR1XS
NCI-H1648 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTNyLkW1O|Qh|ryP M4m3SnNCVkeHUh?=
CAKI-1 M2Xsfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXNTmlKSzVyPUOwMlc4ODJizszN MXjTRW5ITVJ?
YKG-1 M2HxXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4j2V2lEPTB;M{GuNFI3OyEQvF2= Mn23V2FPT0WU
A2058 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vWdWlEPTB;M{GuNVE3PCEQvF2= M37H[HNCVkeHUh?=
A375 M1;SXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFH1VlBKSzVyPUOxMlE3QTZizszN M3nub3NCVkeHUh?=
SNB75 NVrzVIJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjZZlNKSzVyPUOxMlI1OzVizszN MUfTRW5ITVJ?
SK-HEP-1 MoDzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTNzLkSyO|Eh|ryP MnTTV2FPT0WU
ME-180 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTNzLk[1OFIh|ryP NFLXS2dUSU6JRWK=
NCI-H209 M3rZU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTNzLkiyOFch|ryP M4PQS3NCVkeHUh?=
HC-1 M4qzdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTN{LkG0OFYh|ryP MWTTRW5ITVJ?
LB373-MEL-D M4Cye2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3LVWJKSzVyPUOyMlE6PzFizszN MWjTRW5ITVJ?
SNU-387 M1PqOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrRZ2hKSzVyPUOyMlMyQTFizszN M3z3cXNCVkeHUh?=
C32 MoDwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTN{LkOzOVMh|ryP NH25clBUSU6JRWK=
EW-13 MmX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXifnVNUUN3ME2zNk46PDB6IN88US=> M3;LbXNCVkeHUh?=
BFTC-905 NUDoVINpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4r4[WlEPTB;M{OuOVE{PiEQvF2= MXTTRW5ITVJ?
NCI-H1299 M1vGOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3xe2ZKSzVyPUOzMlU3OjFizszN NXv0ZnpTW0GQR1XS
LU-135 NH3CcXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXEOlU6UUN3ME2zN{45ODFizszN MkfTV2FPT0WU
NCI-H2122 MljES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLETWM2OD1|Mz65PVY3KM7:TR?= NF;TTJBUSU6JRWK=
SK-LMS-1 NF3yRXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTN2LkSxNFch|ryP MlrRV2FPT0WU
LNCaP-Clone-FGC M{Ptbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTN2Lki1NVUh|ryP M1TiTXNCVkeHUh?=
NCI-H1092 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF65PHVKSzVyPUO1MlI4PDdizszN Mn;sV2FPT0WU
MS-1 NH7jU2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWL6TWZxUUN3ME2zOU4{ODN6IN88US=> NXLVbZBnW0GQR1XS
KYSE-510 NYTlcXJ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFftR4VKSzVyPUO1MlUxPDJizszN MkCzV2FPT0WU
NCI-H1793 Mn3yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTxZ4hKSzVyPUO1MlY2PDVizszN Mn\EV2FPT0WU
MIA-PaCa-2 NYHwTXhLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7PTWM2OD1|Nj6wOFk3KM7:TR?= NIT5cmRUSU6JRWK=
EW-22 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnWVGtKSzVyPUO2MlQxPzJizszN NV3LUZZIW0GQR1XS
IGR-1 NUDESpJlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTN4LkixPFQh|ryP M37RenNCVkeHUh?=
HT-1080 M3jnPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYraNplNUUN3ME2zO{4yOjVizszN NU\ERnVwW0GQR1XS
M14 M1fIRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHKRnpKSzVyPUO3MlE3PDJizszN NX32dHFLW0GQR1XS
786-0 M4\VOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrMO2h5UUN3ME2zO{4zPzl2IN88US=> M4\yOXNCVkeHUh?=
MZ2-MEL M3HsWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTN5LkS1NFEh|ryP MXvTRW5ITVJ?
NCI-H510A MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTN5Lkm0NVIh|ryP NXrMfGVIW0GQR1XS
LAN-6 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYWwR3JJUUN3ME2zO{46PTh{IN88US=> NGf2eXhUSU6JRWK=
SW620 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jYdWlEPTB;M{iuOFk4PCEQvF2= NYLXdpc5W0GQR1XS
LB2241-RCC MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTN7LkiyNFUh|ryP MULTRW5ITVJ?
Detroit562 NEP0b4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37EZWlEPTB;NECuNVI3QCEQvF2= MnG0V2FPT0WU
HN MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;SNpZKSzVyPUSwMlE4QDJizszN M2Hub3NCVkeHUh?=
HCT-15 NH64c5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2C1b2lEPTB;NECuOVkxPyEQvF2= MUPTRW5ITVJ?
C2BBe1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnjWWFlUUN3ME20NE46OTV5IN88US=> MnLTV2FPT0WU
A498 M3TPWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zwdmlEPTB;NEGuN|AyPSEQvF2= M4j2WnNCVkeHUh?=
SK-MEL-24 M2TNNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTRzLkS3NlUh|ryP M2LYSHNCVkeHUh?=
OVCAR-5 NHjVWXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkWxTWM2OD12MT63O|Y4KM7:TR?= NXr3c3VOW0GQR1XS
NCI-H1792 MnvRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHQTWM2OD12MT65PFIyKM7:TR?= MUnTRW5ITVJ?
KOSC-2 M{n4Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{i4eWlEPTB;NEKuNlY6QSEQvF2= NG[0dZlUSU6JRWK=
Mo-T NXzJTINxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnVTWM2OD12Mj64PVU5KM7:TR?= MYPTRW5ITVJ?
CFPAC-1 MmrFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvmOlNKSzVyPUSzMlQ6PDRizszN MXLTRW5ITVJ?
CAL-51 M1\IcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1f6PGlEPTB;NEOuOVYxPSEQvF2= MWfTRW5ITVJ?
RH-18 NWTFVItjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTR|LkiwOUDPxE1? MV3TRW5ITVJ?
EC-GI-10 NYn5eIhzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjmdoFjUUN3ME20N{45OzR5IN88US=> MlyzV2FPT0WU
HSC-2 NVTpTHlET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTR2LkCwPUDPxE1? MnfYV2FPT0WU
ML-2 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDETWM2OD12NT6yOlIyKM7:TR?= NEHpNY1USU6JRWK=
KNS-81-FD MmDzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHXTWM2OD12NT63N|Y2KM7:TR?= NVuzbIlsW0GQR1XS
NB6 NF3FblJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnJOWNVUUN3ME20Ok4yOTFizszN NIGxc3JUSU6JRWK=
MCF7 M1G3[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4i5SmlEPTB;NE[uOVU{OyEQvF2= MWfTRW5ITVJ?
P30-OHK MljaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LSR2lEPTB;NE[uPFEyPyEQvF2= MWrTRW5ITVJ?
BPH-1 Mo[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTR4Lkm4NFUh|ryP MnnUV2FPT0WU
U251 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITJUpJKSzVyPUS2Mlk6PCEQvF2= NUTYUXU{W0GQR1XS
MKN1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\POmlEPTB;NEeuOVE{PyEQvF2= M{SwXHNCVkeHUh?=
A431 Mm\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXU[JVFUUN3ME20O{45OzN6IN88US=> NHjVPIRUSU6JRWK=
C8166 MnvXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITjdopKSzVyPUS5MlIxOzlizszN MlnKV2FPT0WU
HEL NXHyWZVNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDPUpltUUN3ME20PU41ODZ2IN88US=> MlHEV2FPT0WU
RMG-I MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrYdYFXUUN3ME20PU41PDR2IN88US=> MXLTRW5ITVJ?
CAL-72 MkXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVi3XJBxUUN3ME20PU43ODd3IN88US=> MmfHV2FPT0WU
SW962 M2THc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3H6N2lEPTB;NEmuPVM{OiEQvF2= M2nEfnNCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo Axitinib exhibits primary inhibition to orthotopically transplanted models such as M24met (melanoma), HCT-116 (colorectal cancer), and SN12C (renal cell carcinoma). [1] Axitinib delays the tumor growth with 11.4 days compared to the controls (p.o. 30 mg/kg) and decreases the Mean Vessels Density (MVD) to 21, compared to 49 in controls, in IGR-N91 flank xenografts. [2] Axitinib significantly inhibits growth and disrupts tumor microvasculature in BT474 breast cancer model at 10-100 mg/kg. [3] Axitinib has shown single-agent activity in variable tumors, including renal cell carcinoma, thyroid cancer, non-small cell lung cancer, and melanoma.

Protocol

Kinase Assay:

[1]

+ Expand

Cellular receptor kinase phosphorylation assay:

Porcine aorta endothelial (PAE) cells, which overexpress full-length VEGFR2, PDGFRβ, Kit, and NIH-3T3, which overexpress murine VEGFR2 (Flk-1) or PDGFRα, are generated. The 96-well plates are coated with 100 μL/well of 2.5 μg/mL anti-VEGFR2 antibody, 0.75 μg/mL anti-PDGFRβ antibody, 0.25 μg/mL anti-PDGFRα antibody, 0.5 μg/mL anti-KIT antibody, or 1.20 μg/mL anti-Flk-1 antibody to prepare ELISA capture plates. Then phosphorylation of RTK is measured by ELISA.
Cell Research:

[2]

+ Expand
  • Cell lines: HUVEC, SH-SY5Y, IGR-N91 and IGR-NB8 cells
  • Concentrations: 1 nM - 10 μM
  • Incubation Time: 72 hours
  • Method:

    Cells are seeded in a 96-well plate at a density of 5 × 104 and cultured for 24 hours. Axitinib is added to the cells at concentrations ranging from 1 nM to 10 μM. Cell viability is measured after 72 hours by MTS tetrazolium substrate and IC50 values are calculated.


    (Only for Reference)
Animal Research:

[3]

+ Expand
  • Animal Models: BT474 breast cancer cells are implanted subcutaneously into Immune-deficient female mice (Nu/nu; age 8-12 weeks).
  • Formulation: 0.5% carboxymethylcellulose (CMC)
  • Dosages: 10, 30 or 100 mg/kg
  • Administration: Oral daily
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 35 mg/mL warmed (90.56 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
0.5% CMC
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 386.47
Formula

C22H18N4OS

CAS No. 319460-85-0
Storage powder
in solvent
Synonyms AG 013736

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03289533 Recruiting Carcinoma Hepatocellular Pfizer September 8 2017 Phase 1
NCT03297606 Recruiting Lymphoma Non-Hodgkin|Multiple Myeloma|Advanced Solid Tumors Canadian Cancer Trials Group|AstraZeneca|Bristol-Myers Squibb|Hoffmann-La Roche|Pfizer October 6 2017 Phase 2
NCT02560012 Terminated Carcinoma Renal Cell The University of Texas Health Science Center Houston January 4 2016 Phase 2
NCT00700258 Recruiting Carcinoma Renal Cell Advanced|Lymphoma Mantle-Cell|Gastrointestinal Stroma Tumors Pfizer January 4 2008 --
NCT03438708 Not yet recruiting Clear Cell Renal Cell Carcinoma University of California San Diego|The Cleveland Clinic March 30 2018 Phase 2
NCT02579811 Active not recruiting Metastatic Renal Cell Cancer Case Comprehensive Cancer Center December 30 2015 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    We would like to store at -80℃ after it dissolved in CMC. Do you have any infomation about the suggested concentration in CMC?

  • Answer:

    Axitinib in 0.5% CMC at up to 30mg/ml is a suspension for oral gavage administration only. We don't suggest customer to freeze down the solution but to make fresh if possible. Customer can store it for 1-2 weeks at 4 degree for continuous use.

VEGFR Signaling Pathway Map

VEGFR Inhibitors with Unique Features

Related VEGFR Products

Tags: buy Axitinib | Axitinib supplier | purchase Axitinib | Axitinib cost | Axitinib manufacturer | order Axitinib | Axitinib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID